Merck & Co., Inc. is 5.2x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $56.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | REGN | MRK |
|---|---|---|
| Market cap | $56.80 B | $294.13 B |
| US-listed rank | #291 | #44 |
| Revenue (latest FY) | $14.34B | $65.01B |
| Net income (latest FY) | $4.50B | $18.25B |
| Net margin | 31.4% | 28.1% |
| P/E (trailing FY) | 12.6 | 16.1 |
| SEC filings | 985 | 996 |
Merck & Co., Inc. is 5.2x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $56.80 B).
In their latest fiscal years, REGENERON PHARMACEUTICALS, INC. reported $14.34B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: REGENERON PHARMACEUTICALS, INC. and Merck & Co., Inc., or browse the full rankings.